Qitai Zhao

Henan Cancer Hospital — China

Medicine · Health Sciences

14h-index927citations73works2.02yr avg

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(32), Immune cells in cancer(27), CAR-T cell therapy research(23), Immunotherapy and Immune Responses(11), Cancer-related gene regulation(10)

Publications73 total

TREM2‐Mediated Cholesterol Efflux in Macrophages Inhibits Anti‐Tumor Immunity via Limitation of CD4 + T and NK Cells

2 cited

Advanced Science·2025· 2 citedOpen Access

Single-cell transcriptomic analyses provide insights into SPP1+ TAM-mediated immune suppression and CD8+ T cell dysfunction in lung cancer

3 cited

Cancer Immunology Immunotherapy·2025· 3 citedOpen Access

HMGB1 inhibits the IFN-γ–induced PD-L1 expression in NSCLC

1 cited

The Journal of Immunology·2025· 1 cited

Single-cell RNA sequencing analysis reveals a lack of CXCL13+ T cell subsets associated with the recurrence of cervical squamous cell carcinoma following concurrent chemoradiotherapy

3 cited

Cancer Immunology Immunotherapy·2025· 3 citedOpen Access

Metabolic profiling of glioblastoma and identification of G0S2 as a metabolic target

Frontiers in Oncology·2025Open Access

Single-cell transcriptomic analyses reveal heterogeneity and key subsets associated with survival and response to PD-1 blockade in cervical squamous cell carcinoma

2 cited

Cancer Cell International·2025· 2 citedOpen Access

Changes in L‐phenylalanine concentration reflect and predict response to anti‐PD‐1 treatment combined with chemotherapy in patients with non‐small cell lung cancer

MedComm·2025Open Access

Distinct immune signatures for predicting the immunotherapy efficacy of esophageal squamous cell carcinoma or adenocarcinoma

1 cited

Cancer Immunology Immunotherapy·2025· 1 citedOpen Access

Table S5 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

2024Open Access

Figure S2 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

2024Open Access

Figure S5 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

2024Open Access

Table S4 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

2024Open Access

Table S2 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

2024Open Access

Figure S6 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

2024Open Access

Figure S7 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

2024Open Access

Figure S4 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

2024Open Access

Table S1 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

2024Open Access

Figure S3 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

2024Open Access

Table S6 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

2024Open Access

Table S3 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

2024Open Access

page 1 of 4Next →

Frequent Co-authors

Yi Zhang(39), Xinfeng Chen(19), Shasha Liu(14), Guohui Qin(11), Jingyao Lian(11), Chaoqi Zhang(10), Chunyi Shen(9), Bin Zhang(9), Lijun Miao(9), Mengjia Song(8), Zhen Zhang(8), Xuan Zhao(8), Congcong Li(8), Yaqing Liu(8), Lijie Song(8), Fuyou Guo(8), Jie Zhao(8), Weiyue Gu(8), Zhen Zhang(7), Dongli Yue(7)